View Archived Issues

June 18, 2018

Vol. 17
No. 117


Hatch Amendment Would Offer Generic Litigants Patent Appeal Choice

Sen. Orrin Hatch (R-Utah) proposes to amend the landmark Hatch-Waxman Act to require generic drugmakers challenging brand patents to choose between inter partes reviews or Hatch-Waxman litigation. Read More

House Passes Bill Cracking Down on Synthetic Opioids

After a flurry of opioid- related bills passed the House earlier last week, the chamber on Friday passed legislation that will limit the availability of synthetic drugs. Read More

Survey Shows U.S. Trust in Pharma Plummets Amid Rising Prices, Opioid Crisis

Americans’ trust in drugmakers plunged in the past year to the lowest level since Edelman launched its annual Trust Barometer survey five years ago. Read More

Montreal Manufacturer Called Out for Cleaning, Testing Issues

The FDA hit Eau Zone Huiles Et Fragrances with a Form 483 after an inspection determined the OTC manufacturer had numerous deficiencies at its Montreal, Quebec facility, including cleaning, testing and drug storage issues. Read More